Sphingosine 1-phosphate turnover (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database

Pyne, Nigel J and Pyne, Susan (2019) Sphingosine 1-phosphate turnover (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database. IUPHAR/BPS Guide to Pharmacology CITE, 2019 (4). ISSN 2633-1020

[img]
Preview
Text (Pyne-Pyne-IUPHAR-BPS-2019-Sphingosine-1-phosphate-turnover)
Pyne_Pyne_IUPHAR_BPS_2019_Sphingosine_1_phosphate_turnover.pdf
Final Published Version
License: Creative Commons ShareAlike 4.0 logo

Download (59kB)| Preview

    Abstract

    S1P (sphingosine 1-phosphate) is a bioactive lipid which, after release from cells via certain transporters, acts as a ligand for a family of five S1P-specific G protein-coupled receptors (S1P1-5). However, it also has a number of intracellular targets. S1P is formed by the ATP-dependent phosphorylation of sphingosine, catalysed by two isoforms of sphingosine kinase (EC 2.7.1.91). It can be dephosphorylated back to sphingosine by sphingosine 1-phosphate phosphatase (EC 3.1.3) or cleaved into phosphoethanolamine and hexadecenal by sphingosine 1-phosphate lyase (EC 4.1.2.27). Recessive mutations in the S1P lyase (SPL) gene underlie a recently identified sphingolipidosis: SPL Insufficiency Syndrome (SPLIS). In general, S1P promotes cell survival, proliferation, migration, adhesion and inhibition of apoptosis. Intracellular S1P affects epigenetic regulation, endosomal processing, mitochondrial function and cell proliferation/senescence. S1P has myriad physiological functions, including vascular development, lymphocyte trafficking and neurogenesis. However, S1P is also involved in a number of diseases such as cancer, inflammation and fibrosis. Therefore, its GPCRs and enzymes of synthesis and degradation are a major focus for drug discovery.